Wells Fargo Initiates Coverage On ORIC Pharmaceuticals with Overweight Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on ORIC Pharmaceuticals with an Overweight rating and set a price target of $20.
October 31, 2024 | 7:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has initiated coverage on ORIC Pharmaceuticals with an Overweight rating and a price target of $20, indicating a positive outlook.
The initiation of coverage with an Overweight rating by a major financial institution like Wells Fargo is a strong positive signal for ORIC Pharmaceuticals. The $20 price target suggests potential upside from current levels, likely leading to increased investor interest and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100